Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lupin launches ivabradine in India

This article was originally published in Scrip

Executive Summary

Lupinhas received approval from the Drugs Controller General of India to launch Ivabrad (ivabradine) 5mg and 7.5mg tablets on the domestic market. Ivabrad is used for the treatment of symptomatic chronic stable angina in patients with coronary artery disease. Traditional heart rate–lowering agents reduce the myocardial contractility, which is harmful when ventricular function is already impaired. Ivabradine reduces heart rate but maintains myocardial contractility and atrioventricular conduction. The cardiac market in India is estimated at about Rs36 billion ($755.3 million) and is growing at 18%. Lupin's cardiovascular business reported sales of Rs1.75 billion in 2007-08 as compared with Rs1.30 billion in 2006-07 and the company has a market share of 5.03%.

You may also be interested in...

Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 

Hair Supplement Linked To Cases Of Severe Hepatitis In France

France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.

AZ Will Sideline ‘Lucky Mistake’ Data To Secure COVID-19 Vaccine Approval

A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts